(Q43229063)

English

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

scientific article published on 4 December 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

prostate cancer

1 reference

based on heuristic

inferred from title

medroxyprogesterone acetate

1 reference

based on heuristic

inferred from title

author name string

Jacques Irani

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Laurent Salomon

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Rostand Oba

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Philippe Bouchard

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Nicolas Mottet

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

publication date

4 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

147-154

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hot flushes and prostate cancer: pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer--a prospective multicenter study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot evaluation of paroxetine for treating hot flashes in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Methodologic lessons learned from hot flash studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Megestrol Acetate for the Prevention of Hot Flashes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiandrogen withdrawal syndrome with cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970338-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70338-9

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43229063&oldid=1984342992"